Titre : Vincristine

Vincristine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Interferon-gamma Release Tests

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment la vincristine est-elle utilisée dans le diagnostic ?

La vincristine n'est pas un outil de diagnostic, mais un traitement pour des cancers diagnostiqués.
Vincristine Cancer Diagnostic
#2

Quels tests précèdent l'administration de vincristine ?

Des tests sanguins et des examens d'imagerie sont effectués pour évaluer la maladie.
Tests de laboratoire Imagerie médicale Vincristine

Symptômes 2

#1

Quels sont les effets secondaires de la vincristine ?

Les effets secondaires incluent neuropathie, constipation, et fatigue.
Effets secondaires Neuropathie Vincristine
#2

La vincristine cause-t-elle des douleurs ?

Oui, elle peut provoquer des douleurs neuropathiques chez certains patients.
Douleur Neuropathie Vincristine

Prévention 2

#1

Peut-on prévenir les effets secondaires de la vincristine ?

Des mesures préventives incluent une surveillance étroite et des médicaments pour les symptômes.
Prévention Effets secondaires Vincristine
#2

Y a-t-il des recommandations avant le traitement par vincristine ?

Oui, une évaluation médicale complète est recommandée avant le traitement.
Évaluation médicale Vincristine Préparation au traitement

Traitements 2

#1

Avec quels médicaments la vincristine est-elle souvent combinée ?

Elle est souvent combinée avec la prednisone et d'autres agents chimiothérapeutiques.
Chimiothérapie Vincristine Prednisone
#2

Comment la vincristine est-elle administrée ?

La vincristine est administrée par voie intraveineuse, généralement en cycle.
Administration intraveineuse Vincristine Chimiothérapie

Complications 2

#1

Quelles complications peuvent survenir avec la vincristine ?

Des complications incluent des infections, des troubles neurologiques et des problèmes gastro-intestinaux.
Complications Infections Vincristine
#2

La vincristine peut-elle causer des problèmes cardiaques ?

Bien que rare, des problèmes cardiaques peuvent survenir, nécessitant une surveillance.
Problèmes cardiaques Vincristine Surveillance médicale

Facteurs de risque 2

#1

Qui est à risque d'effets indésirables de la vincristine ?

Les patients âgés et ceux avec des antécédents de neuropathie sont à risque accru.
Facteurs de risque Neuropathie Vincristine
#2

Les antécédents médicaux influencent-ils le traitement par vincristine ?

Oui, des antécédents de maladies neurologiques peuvent affecter le traitement.
Antécédents médicaux Vincristine Neurologie
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vincristine : Questions médicales les plus fréquentes", "headline": "Vincristine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vincristine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-27", "dateModified": "2025-02-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vincristine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Alcaloïdes de Vinca", "url": "https://questionsmedicales.fr/mesh/D014748", "about": { "@type": "MedicalCondition", "name": "Alcaloïdes de Vinca", "code": { "@type": "MedicalCode", "code": "D014748", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827" } } }, "about": { "@type": "MedicalCondition", "name": "Vincristine", "alternateName": "Vincristine", "code": { "@type": "MedicalCode", "code": "D014750", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Wenjian Yang", "url": "https://questionsmedicales.fr/author/Wenjian%20Yang", "affiliation": { "@type": "Organization", "name": "Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Deqing Pei", "url": "https://questionsmedicales.fr/author/Deqing%20Pei", "affiliation": { "@type": "Organization", "name": "Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Cheng Cheng", "url": "https://questionsmedicales.fr/author/Cheng%20Cheng", "affiliation": { "@type": "Organization", "name": "Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "William E Evans", "url": "https://questionsmedicales.fr/author/William%20E%20Evans", "affiliation": { "@type": "Organization", "name": "Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Richard H Ho", "url": "https://questionsmedicales.fr/author/Richard%20H%20Ho", "affiliation": { "@type": "Organization", "name": "Vanderbilt University Medical Center, Nashville, TN." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Differentially expressed transcript isoforms associate with resistance to tuberculin skin test and interferon gamma release assay conversion.", "datePublished": "2023-04-14", "url": "https://questionsmedicales.fr/article/37058459", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0284498" } }, { "@type": "ScholarlyArticle", "name": "Monocyte Transcriptional Responses to Mycobacterium tuberculosis Associate with Resistance to Tuberculin Skin Test and Interferon Gamma Release Assay Conversion.", "datePublished": "2022-06-13", "url": "https://questionsmedicales.fr/article/35695527", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1128/msphere.00159-22" } }, { "@type": "ScholarlyArticle", "name": "Development of an Interferon-Gamma Release Assay (IGRA) to Aid Diagnosis of Histoplasmosis.", "datePublished": "2022-10-03", "url": "https://questionsmedicales.fr/article/36190260", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1128/jcm.01128-22" } }, { "@type": "ScholarlyArticle", "name": "Serial testing of latent tuberculosis infection in patients with diabetes mellitus using interferon-gamma release assay, tuberculin skin test, and creation tuberculin skin test.", "datePublished": "2022-12-01", "url": "https://questionsmedicales.fr/article/36530654", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2022.1025550" } }, { "@type": "ScholarlyArticle", "name": "Prevalence of latent Mycobacterium tuberculosis infection in hematopoietic stem cell transplantation comparing tuberculin skin test and interferon-gamma release assay.", "datePublished": "2023-05-01", "url": "https://questionsmedicales.fr/article/37126131", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10096-023-04613-w" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indolizine", "item": "https://questionsmedicales.fr/mesh/D007212" }, { "@type": "ListItem", "position": 6, "name": "Indolizidines", "item": "https://questionsmedicales.fr/mesh/D054836" }, { "@type": "ListItem", "position": 7, "name": "Alcaloïdes indoliques", "item": "https://questionsmedicales.fr/mesh/D026121" }, { "@type": "ListItem", "position": 8, "name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine", "item": "https://questionsmedicales.fr/mesh/D046948" }, { "@type": "ListItem", "position": 9, "name": "Alcaloïdes de Vinca", "item": "https://questionsmedicales.fr/mesh/D014748" }, { "@type": "ListItem", "position": 10, "name": "Vincristine", "item": "https://questionsmedicales.fr/mesh/D014750" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vincristine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vincristine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vincristine", "description": "Comment la vincristine est-elle utilisée dans le diagnostic ?\nQuels tests précèdent l'administration de vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Interferon-gamma+Release+Tests#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vincristine", "description": "Quels sont les effets secondaires de la vincristine ?\nLa vincristine cause-t-elle des douleurs ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Interferon-gamma+Release+Tests#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vincristine", "description": "Peut-on prévenir les effets secondaires de la vincristine ?\nY a-t-il des recommandations avant le traitement par vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Interferon-gamma+Release+Tests#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vincristine", "description": "Avec quels médicaments la vincristine est-elle souvent combinée ?\nComment la vincristine est-elle administrée ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Interferon-gamma+Release+Tests#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vincristine", "description": "Quelles complications peuvent survenir avec la vincristine ?\nLa vincristine peut-elle causer des problèmes cardiaques ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Interferon-gamma+Release+Tests#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vincristine", "description": "Qui est à risque d'effets indésirables de la vincristine ?\nLes antécédents médicaux influencent-ils le traitement par vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Interferon-gamma+Release+Tests#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la vincristine est-elle utilisée dans le diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La vincristine n'est pas un outil de diagnostic, mais un traitement pour des cancers diagnostiqués." } }, { "@type": "Question", "name": "Quels tests précèdent l'administration de vincristine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie sont effectués pour évaluer la maladie." } }, { "@type": "Question", "name": "Quels sont les effets secondaires de la vincristine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent neuropathie, constipation, et fatigue." } }, { "@type": "Question", "name": "La vincristine cause-t-elle des douleurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des douleurs neuropathiques chez certains patients." } }, { "@type": "Question", "name": "Peut-on prévenir les effets secondaires de la vincristine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des mesures préventives incluent une surveillance étroite et des médicaments pour les symptômes." } }, { "@type": "Question", "name": "Y a-t-il des recommandations avant le traitement par vincristine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une évaluation médicale complète est recommandée avant le traitement." } }, { "@type": "Question", "name": "Avec quels médicaments la vincristine est-elle souvent combinée ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle est souvent combinée avec la prednisone et d'autres agents chimiothérapeutiques." } }, { "@type": "Question", "name": "Comment la vincristine est-elle administrée ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La vincristine est administrée par voie intraveineuse, généralement en cycle." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la vincristine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des infections, des troubles neurologiques et des problèmes gastro-intestinaux." } }, { "@type": "Question", "name": "La vincristine peut-elle causer des problèmes cardiaques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Bien que rare, des problèmes cardiaques peuvent survenir, nécessitant une surveillance." } }, { "@type": "Question", "name": "Qui est à risque d'effets indésirables de la vincristine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les patients âgés et ceux avec des antécédents de neuropathie sont à risque accru." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils le traitement par vincristine ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies neurologiques peuvent affecter le traitement." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 21/02/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Wenjian Yang

3 publications dans cette catégorie

Affiliations :
  • Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Deqing Pei

3 publications dans cette catégorie

Affiliations :
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Cheng Cheng

3 publications dans cette catégorie

Affiliations :
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

William E Evans

3 publications dans cette catégorie

Affiliations :
  • Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Richard H Ho

3 publications dans cette catégorie

Affiliations :
  • Vanderbilt University Medical Center, Nashville, TN.

Sima Jeha

2 publications dans cette catégorie

Affiliations :
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Ching-Hon Pui

2 publications dans cette catégorie

Affiliations :
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Mirjam E van de Velde

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

Aniek Uittenboogaard

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Gertjan J L Kaspers

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Esperanza Herradón

2 publications dans cette catégorie

Affiliations :
  • Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
  • Unidad Asociada al Instituto de Química Medica (IQM) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos, Alcorcón, Spain.
  • High Performance Research Group in Experimental Pharmacology (Pharmakom-URJC), URJC, Alcorcón, Spain.
Publications dans "Vincristine" :

Visitación López-Miranda

2 publications dans cette catégorie

Affiliations :
  • Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
  • Unidad Asociada al Instituto de Química Medica (IQM) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos, Alcorcón, Spain.
  • High Performance Research Group in Experimental Pharmacology (Pharmakom-URJC), URJC, Alcorcón, Spain.
Publications dans "Vincristine" :

Yang Li

2 publications dans cette catégorie

Affiliations :
  • Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, PR China.

Jing Huang

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Mental Health Institute of the Second Xiangya Hospital, Central South University, Chinese National Clinical Research Center on Mental Disorders (xiangya), Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China.
Publications dans "Vincristine" :

Johnny Donovan

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Zicheng Deng

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, United States.
  • Center for Lung Regenerative Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Fenghua Bian

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Samriddhi Shukla

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Jose Gomez-Arroyo

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • Division of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, United States.

Donglu Shi

2 publications dans cette catégorie

Affiliations :
  • The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, United States.

Sources (10000 au total)

Differentially expressed transcript isoforms associate with resistance to tuberculin skin test and interferon gamma release assay conversion.

A mechanistic understanding of uncommon immune outcomes such as resistance to infection has led to the development of novel therapies. Using gene level analytic methods, we previously found distinct m... Using transcript isoform analyses, we aimed to identify novel RSTR-associated genes hypothesizing that previous gene-level differential expression analysis obscures isoform-specific differences that c... Monocytes from 49 RSTR versus 52 subjects with latent Mtb infection (LTBI) were infected with M. tuberculosis (H37Rv) or left unstimulated (media) prior to RNA isolation and sequencing. RSTR-associate... We identified 81 differentially expressed transcripts (DETs) in 70 genes (FDR <0.05) comparing RSTR and LTBI phenotypes with the majority (n = 79 DETs) identified under Mtb-stimulated conditions. Seve... Transcript isoform-specific analyses identify transcriptional associations, such as those associated with resistance to TST/IGRA conversion, that are obscured when using gene-level approaches. These f...

Monocyte Transcriptional Responses to Mycobacterium tuberculosis Associate with Resistance to Tuberculin Skin Test and Interferon Gamma Release Assay Conversion.

Heavy exposure to Mycobacterium tuberculosis, the etiologic agent of tuberculosis (TB) and among the top infectious killers worldwide, results in infection that is cleared, contained, or progresses to...

Serial testing of latent tuberculosis infection in patients with diabetes mellitus using interferon-gamma release assay, tuberculin skin test, and creation tuberculin skin test.

Diabetes mellitus (DM) patients with latent tuberculosis infection (LTBI) have an increased risk of developing active tuberculosis (TB) due to impaired immunity. The performance of currently available... A prospective study was conducted to investigate the status of LTBI in patients with confirmed T2DM. At the baseline survey, the prevalence of LTBI was tested using interferon-gamma release assay (IGR... A total of 404 participants with T2DM were included in the study. At baseline, after excluding active TB, the prevalence of LTBI identified by TST (≥ 10 mm), C-TST (≥ 5 mm) and IGRA (≥ 0.35 IU/ml) wer... In studied patients with T2DM, C-TST showed higher consistency with IGRA as compared to TST. The present of conversion observed in serial testing suggested that boosting effect of skin testing should ...

Prevalence of latent Mycobacterium tuberculosis infection in hematopoietic stem cell transplantation comparing tuberculin skin test and interferon-gamma release assay.

The aim of this study was to evaluate the prevalence of latent Mycobacterium tuberculosis infection in hematopoietic stem cell transplantation candidates, using tuberculin skin test and QuantiFERON-TB...

Assay for interferon gamma release as a novel marker in pediatric patients with systemic lupus erythematosus.

The interferon-gamma (IFN-γ) release assay (IGRA) is an important laboratory diagnosis for latent Mycobacterium tuberculosis (TB) infection. The TB-IGRA measures the release of IFN-γ from peripheral b... We have analyzed the clinical data of 776 children who are underwent TB-IGRA testing in the Department of Allergy and Rheumatology of Guangzhou Women and Children's Medical Center from 2018 to 2020. T... The TB Ag-NL levels were significantly higher in patients with active SLE than those in inactive SLE (p = 0.0002). The TB Ag-NL levels were positively correlated with the SLE disease activity index (S... The detection of IFN-γ release levels by the TB-IGRA may be useful to assess SLE disease activity in pediatric patients with active SLE....

Interferon gamma release assays for diagnosis of osteoarticular tuberculosis: A systematic review and meta-analysis.

Although the Interferon Gamma Release Assays (IGRA) is often used to identify latent tuberculosis, it also plays a crucial role in diagnosing active extrapulmonary tuberculosis. Some studies have asse... We searched PubMed, Embase, and Cochran databases. We obtained literature related to the diagnosis of OATB by IGRA, and the retrieval period was from the establishment of the database to June 2021. Th... We included seven studies involving 643 subjects in diagnosing OATB by IGRA. The comprehensive sensitivity and specificity were 0.84 (95% CI, 0.70-0.92) and 0.78 (95% CI, 0.66-0.87), respectively. The... In blood samples, the diagnostic accuracy of IGRAS is poor in patients with suspected OAT. We conclude that IGRA may not be appropriate for patients with OATB....

Interferon Gamma Release Assay Results and Testing Trends Among Patients Younger Than 2 Years Old at Two US Health Centers.

Interferon-gamma release assays (IGRAs) are approved for children ≥2 years old to aid in diagnosis of Mycobacterium tuberculosis (TB) infection and disease. Tuberculin skin tests (TSTs) continue to be... We performed a retrospective cohort study of IGRA use in patients <2 years old in 2 large Boston healthcare systems. The primary outcome was the proportion of valid versus invalid/indeterminate IGRA r... A total of 321 IGRA results were analyzed; 308 tests (96%) were valid and 13 (4%) were invalid/indeterminate. Thirty-seven IGRAs were obtained in immunocompromised patients; the proportion of invalid/... The high proportion of valid IGRA test results in patients <2 years of age in a low TB prevalence setting in combination with the known logistical and interpretation challenges associated with TSTs su...